Skip to main content

Hikma Pharmaceuticals Plc Value Stock - Dividend - Research Selection

Hikma Pharmaceuticals Plc

ISIN: GB00B0LCW083, WKN: A0HG69

Market price date: 01.06.2021
Market price: 34,90 USD




Hikma Pharmaceuticals Plc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 02-03-2021
Cash flow
Net operating cash flow 464.000.000
Capital Expenditures -224.000.000
Free cash flow 240.000.000
Balance sheet
Total Equity 2.135.000.000
Liabilities & Shareholders equity 4.135.000.000
Income statement
Net income 431.000.000
Eps (diluted) 1,870
Diluted shares outstanding 230.499.000
Net sales/revenue 2.341.000.000

Fundamental ratios calculated on: 01-06-2021

Ratios
Key figures 01-06-2021
Cash flow
P/C 17,34
   
P/FC 33,52
Balance sheet
ROI10,42
ROE51,63
Income statement
P/E18,66
Div. Yield1,32%
P/B3,77
P/S3,44


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolHKMPF
Market Capitalization8.044.414.976,00 USD
Country
IndicesFTSE 100
Sectors
Raw Data SourceIFRS in Millionen USD
Stock Split
Internetwww.hikma.com


Description of the company

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.hikma.com